Natixis Advisors LLC Makes New $879,000 Investment in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Natixis Advisors LLC bought a new stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 14,968 shares of the company’s stock, valued at approximately $879,000.

A number of other institutional investors and hedge funds have also modified their holdings of APGE. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Apogee Therapeutics by 21.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock worth $94,000 after buying an additional 285 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Apogee Therapeutics during the second quarter worth about $143,000. Kennedy Capital Management LLC acquired a new position in Apogee Therapeutics in the first quarter valued at about $212,000. Arizona State Retirement System increased its holdings in shares of Apogee Therapeutics by 4.5% in the second quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock worth $236,000 after acquiring an additional 258 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in shares of Apogee Therapeutics by 26.3% during the second quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock worth $253,000 after purchasing an additional 1,340 shares during the period. 79.04% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on APGE. Guggenheim increased their price objective on shares of Apogee Therapeutics from $95.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday. Canaccord Genuity Group began coverage on Apogee Therapeutics in a research note on Monday. They issued a “buy” rating and a $89.00 target price on the stock. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a report on Monday. They issued a “buy” rating and a $89.00 price objective on the stock. Finally, Wedbush restated an “outperform” rating and set a $87.00 target price on shares of Apogee Therapeutics in a report on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $83.50.

Apogee Therapeutics Stock Performance

Shares of APGE opened at $44.70 on Thursday. The firm’s 50-day simple moving average is $54.01 and its 200 day simple moving average is $48.57. The firm has a market cap of $2.01 billion, a P/E ratio of -18.41 and a beta of 2.93. Apogee Therapeutics, Inc. has a 52 week low of $16.39 and a 52 week high of $72.29.

Insider Buying and Selling

In related news, insider Carl Dambkowski sold 6,665 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $56.26, for a total value of $374,972.90. Following the completion of the transaction, the insider now owns 274,128 shares in the company, valued at $15,422,441.28. This trade represents a 2.37 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael Thomas Henderson sold 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $47.62, for a total transaction of $1,904,800.00. Following the sale, the chief executive officer now directly owns 1,394,487 shares in the company, valued at $66,405,470.94. The trade was a 2.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 114,995 shares of company stock valued at $6,128,295. Insiders own 36.10% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.